Drugs / Quadrivalent influenza modRNA vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05540522 | Sep 2022 → Mar 2024 | influenza | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent influenza modRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05540522 ↗ |
| Known as | qIRV | “quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 seasonally recommended strains” NCT05540522 ↗ |
| Modality | Messenger RNA (mRNA) | “Nucleoside-modified messenger RNA (modRNA) influenza vaccines” PMID 41259756 ↗ Nov 2025 |